Tandem Diabetes Care (TNDM) Total Debt (2013 - 2025)

Tandem Diabetes Care (TNDM) posted Total Debt of $40.7 million for Q1 2025, little changed on a QoQ basis from $40.7 million in Q4 2024.

Tandem Diabetes Care (TNDM) Total Debt (2013 - 2025) Analysis & Trends

Tandem Diabetes Care's Total Debt history runs 8 years deep, the most recent figure standing at $40.7 million for Q1 2025.

Quarterly Total Debt changed N/A year-over-year to $40.7 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $40.7 million (changed N/A YoY) and the FY2024 annual result came in at $40.7 million, changed N/A from the prior year.
Total Debt was $40.7 million for Q1 2025 at Tandem Diabetes Care, roughly flat from $40.7 million in the prior quarter.
Across five years, Total Debt topped out at $40.7 million in Q1 2025 and bottomed at $40.5 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	34.05 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	14.72 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	27.96 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	11.03 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	598.50 Mn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	9.48 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	10.14 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	3.18 Bn
10	Tandem Diabetes Care	1.16 Bn	587.46 Mn	136.79 Mn	-

Download Data